MEDNAX acquires radiology group Jefferson in latest industry swoop
The US health solutions co...
MEDNAX has made its third radiology services practice acquisition of 2017 after adding Jefferson Radiology to its portfolio.
The US health solutions company, based in Florida and with annual revenues of over $2bn, expands its radiology services with the deal, further establishing it as the partner of choice for leading radiology practices.
The news comes two months after MEDNAX acquired the Miami-based Radiology Associates and eight months after joining forces with Radiology Alliance in Kentucky.
“We are excited about the growth of radiology physician services at MEDNAX,” said Roger Medel, M.D, CEO of MEDNAX.
“Our ability to attract leading radiology providers such as Jefferson Radiology, further enhances our integrated physician services offering.”
Jefferson is the largest private radiology group in Connecticut, working with over 60 physicians, providing exclusive services to seven regional hospitals.
Its own CEO Ethan Foxman added: “We wanted to be part of a team that is leading the best practices in radiology and reshaping the next generation of how radiology services will be delivered.
“We were drawn to the energy and excitement of MEDNAX’S mission to build the top radiology platform nationally and beyond.”
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”